|
BR112014015197A8
(pt)
|
2011-12-21 |
2017-06-13 |
Novira Therapeutics Inc |
agentes antivirais de hepatite b
|
|
KR102271574B1
(ko)
|
2012-08-28 |
2021-07-01 |
얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 |
설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
|
|
WO2014131847A1
(en)
|
2013-02-28 |
2014-09-04 |
Janssen R&D Ireland |
Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
|
|
MX353412B
(es)
|
2013-04-03 |
2018-01-10 |
Janssen Sciences Ireland Uc |
Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
|
|
TWI733288B
(zh)
|
2013-05-17 |
2021-07-11 |
愛爾蘭商健生科學愛爾蘭無限公司 |
胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途
|
|
DK2997019T3
(en)
|
2013-05-17 |
2018-12-03 |
Janssen Sciences Ireland Uc |
SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B
|
|
HRP20180791T1
(hr)
|
2013-07-25 |
2018-09-07 |
Janssen Sciences Ireland Uc |
Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b
|
|
CA2923712C
(en)
|
2013-10-23 |
2021-11-02 |
Janssen Sciences Ireland Uc |
Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
|
|
US9169212B2
(en)
|
2014-01-16 |
2015-10-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
US10392349B2
(en)
|
2014-01-16 |
2019-08-27 |
Novira Therapeutics, Inc. |
Azepane derivatives and methods of treating hepatitis B infections
|
|
CA2936947A1
(en)
|
2014-02-05 |
2015-08-13 |
Novira Therapeutics, Inc. |
Combination therapy for treatment of hbv infections
|
|
TW201620893A
(zh)
|
2014-02-06 |
2016-06-16 |
健生科學愛爾蘭無限公司 |
磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途
|
|
TWI874834B
(zh)
|
2014-12-18 |
2025-03-01 |
瑞士商赫孚孟拉羅股份公司 |
四氫-吡啶并[3,4-b]吲哚雌激素受體調節劑及其用途
|
|
WO2016146591A1
(en)
*
|
2015-03-16 |
2016-09-22 |
Astrazeneca Ab |
Combination treatment
|
|
JP2018510159A
(ja)
|
2015-03-19 |
2018-04-12 |
ノヴィラ・セラピューティクス・インコーポレイテッド |
アゾカン及びアゾナン誘導体及びｂ型肝炎感染症の治療法
|
|
US10087191B2
(en)
|
2015-06-16 |
2018-10-02 |
Jiangsu Hengrui Medicine Co., Ltd. |
Piperidine derivative and preparation method and pharmaceutical use thereof
|
|
US10875876B2
(en)
|
2015-07-02 |
2020-12-29 |
Janssen Sciences Ireland Uc |
Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
TW201718496A
(zh)
|
2015-09-29 |
2017-06-01 |
諾維拉治療公司 |
B型肝炎抗病毒劑之晶型
|
|
KR20240142622A
(ko)
*
|
2015-10-01 |
2024-09-30 |
올레마 파마슈티컬스 인코포레이티드 |
테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
|
|
JP6592197B2
(ja)
*
|
2015-11-12 |
2019-10-16 |
浙江海正薬業股▲ふん▼有限公司Ｚｈｅｊｉａｎｇ Ｈｉｓｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ ＣＯ．，ＬＴＤ． |
アクリル酸誘導体、製造方法、および医薬としてのその使用
|
|
LT3386500T
(lt)
|
2015-12-09 |
2022-12-27 |
The Board Of Trustees Of The University Of Illinois |
Selektyvūs estrogenų receptorių slopintojai benzotiofeno pagrindu
|
|
CA3006683A1
(en)
|
2015-12-22 |
2017-06-29 |
Jiangsu Hengrui Medicine Co., Ltd. |
Benzopiperidine derivative, preparation method thereof and medical use thereof
|
|
KR102479822B1
(ko)
|
2016-02-05 |
2022-12-21 |
인벤티스바이오 엘엘씨 |
선택적 에스트로겐 수용체 분해제 및 이들의 용도
|
|
KR20220071293A
(ko)
*
|
2016-04-01 |
2022-05-31 |
리커리엄 아이피 홀딩스, 엘엘씨 |
에스트로겐 수용체 조절제
|
|
AU2017248828A1
(en)
|
2016-04-15 |
2018-11-01 |
Janssen Sciences Ireland Uc |
Combinations and methods comprising a capsid assembly inhibitor
|
|
WO2017182493A1
(en)
|
2016-04-20 |
2017-10-26 |
Astrazeneca Ab |
Indazole derivatives for use in down-regulation of the estrogen receptor for the treatment of cancer
|
|
JP7131773B2
(ja)
*
|
2016-04-29 |
2022-09-06 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
ホルモン受容体に関連する転写活性の標的尺度
|
|
WO2017197904A2
(zh)
*
|
2016-05-08 |
2017-11-23 |
上海诚妙医药科技有限公司 |
帕布昔利布的新晶型及其制备方法及其用途
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
ES2990061T3
(es)
|
2016-05-10 |
2024-11-28 |
C4 Therapeutics Inc |
Degronímeros espirocíclicos para la degradación de proteínas diana
|
|
CN109843882A
(zh)
|
2016-06-16 |
2019-06-04 |
豪夫迈·罗氏有限公司 |
四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
|
|
EP3472162B1
(en)
*
|
2016-06-16 |
2021-11-17 |
F. Hoffmann-La Roche AG |
Heteroaryl estrogen receptor modulators and uses thereof
|
|
WO2018001232A1
(zh)
*
|
2016-06-29 |
2018-01-04 |
浙江海正药业股份有限公司 |
丙烯酸类衍生物及其制备方法和其在医药上的用途
|
|
RU2019102647A
(ru)
|
2016-07-01 |
2020-08-03 |
Г1 Терапьютикс, Инк. |
Антипролиферационные средства на основе пиримидина
|
|
US10149839B2
(en)
|
2016-07-25 |
2018-12-11 |
Astrazeneca Ab |
Chemical compounds
|
|
CN107814798B
(zh)
*
|
2016-09-14 |
2020-11-03 |
四川科伦博泰生物医药股份有限公司 |
3-取代丙烯酸类化合物及其制备方法和用途
|
|
JP7050770B2
(ja)
*
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
|
EP3640251B1
(en)
|
2016-10-24 |
2021-12-08 |
Astrazeneca AB |
6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
|
|
MX2019008158A
(es)
|
2017-01-06 |
2019-12-09 |
G1 Therapeutics Inc |
Terapia de combinacion para el tratamiento del cancer.
|
|
WO2018130123A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的五环类化合物及其应用
|
|
WO2018130124A1
(zh)
*
|
2017-01-11 |
2018-07-19 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的三环类化合物及其应用
|
|
PL3494116T3
(pl)
*
|
2017-01-30 |
2020-04-30 |
Astrazeneca Ab |
Modulatory receptora estrogenowego
|
|
JP7227912B2
(ja)
|
2017-02-08 |
2023-02-24 |
ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド |
キメラ抗原受容体の調節
|
|
KR20190117582A
(ko)
|
2017-02-10 |
2019-10-16 |
쥐원 쎄라퓨틱스, 인크. |
벤조티오펜 에스트로겐 수용체 조정제
|
|
CN108864080B
(zh)
*
|
2017-05-09 |
2021-10-15 |
南京圣和药业股份有限公司 |
作为选择性雌激素受体下调剂的四环类化合物及其应用
|
|
CN110536888B
(zh)
*
|
2017-06-20 |
2022-07-26 |
江苏恒瑞医药股份有限公司 |
一种苯并哌啶类衍生物的盐、其晶型及盐、其晶型的制备方法
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
WO2019006393A1
(en)
|
2017-06-29 |
2019-01-03 |
G1 Therapeutics, Inc. |
Morphic forms of git38 and methods of manufacture thereof
|
|
AU2018351050B2
(en)
|
2017-10-18 |
2025-09-18 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
EA038160B1
(ru)
*
|
2017-11-30 |
2021-07-15 |
Астразенека Аб |
Модуляторы рецептора эстрогена
|
|
CN109867659A
(zh)
*
|
2017-12-04 |
2019-06-11 |
江苏恒瑞医药股份有限公司 |
苯并哌啶类衍生物的制备方法
|
|
US10519152B2
(en)
|
2017-12-21 |
2019-12-31 |
Astrazeneca Ab |
Compounds and their use in treating cancer
|
|
WO2019162429A1
(en)
*
|
2018-02-23 |
2019-08-29 |
Center For Intelligent Research In Crystal Engineering, S.L. |
Cocrystals of ubiquinol and compositions comprising them
|
|
MX2020009531A
(es)
|
2018-03-14 |
2020-10-05 |
Janssen Sciences Ireland Unlimited Co |
Regimen posologico del modulador del ensamblaje de la capside.
|
|
CA3099155A1
(en)
|
2018-05-14 |
2019-11-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
WO2019228443A1
(en)
*
|
2018-05-30 |
2019-12-05 |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
Selective estrogen receptor downregulators and uses thereof
|
|
CR20200621A
(es)
|
2018-06-21 |
2021-02-03 |
Hoffmann La Roche |
Formas sólidas de 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3 fluoropropil)azetidin-3-il)amino)fenil)-3-(metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)-2,2-difluoropropan-1-ol y procesos para preparar compuestos tricíclicos fusionados que comprenden un resto fenilo o piridinilo sustituido, incluidos métodos para su uso
|
|
JP2021529757A
(ja)
|
2018-07-03 |
2021-11-04 |
ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ |
小胞体ストレス応答の活性剤
|
|
CN120698983A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
MX2021007687A
(es)
|
2018-12-24 |
2021-10-13 |
Inventisbio Co Ltd |
Sales novedosas de degradadores selectivos de receptores de estrogeno.
|
|
WO2020169784A1
(en)
|
2019-02-22 |
2020-08-27 |
Janssen Sciences Ireland Unlimited Company |
Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
AR119732A1
(es)
|
2019-05-06 |
2022-01-05 |
Janssen Sciences Ireland Unlimited Co |
Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
|
|
CA3138197A1
(en)
|
2019-05-14 |
2020-11-19 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20220034129A
(ko)
|
2019-07-07 |
2022-03-17 |
올레마 파마슈티컬스 인코포레이티드 |
에스트로겐 수용체 길항제 요법
|
|
KR20220044528A
(ko)
|
2019-08-06 |
2022-04-08 |
리커리엄 아이피 홀딩스, 엘엘씨 |
돌연변이체를 치료하기 위한 에스트로겐 수용체 조절제
|
|
AU2020380211A1
(en)
*
|
2019-11-04 |
2022-05-19 |
Recurium Ip Holdings, Llc |
Salts and forms of an estrogen receptor modulator
|
|
EP4058464A1
(en)
|
2019-11-13 |
2022-09-21 |
Nuvation Bio Inc. |
Anti-cancer nuclear hormone receptor-targeting compounds
|
|
KR20220119415A
(ko)
|
2019-12-20 |
2022-08-29 |
씨4 테라퓨틱스, 인코포레이티드 |
Egfr 분해를 위한 이소인돌리논 및 인다졸 화합물
|
|
CN114746424B
(zh)
|
2020-01-10 |
2023-06-16 |
江苏恒瑞医药股份有限公司 |
三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用
|
|
TW202146412A
(zh)
|
2020-03-05 |
2021-12-16 |
美商Ｃ４醫藥公司 |
用於標靶降解brd9之化合物
|
|
CA3169679A1
(en)
|
2020-03-06 |
2021-09-10 |
Olema Pharmaceuticals, Inc. |
Methods of treating estrogen receptor-associated diseases
|
|
MX2022013258A
(es)
|
2020-04-24 |
2022-11-14 |
Astrazeneca Ab |
Formulaciones farmaceuticas.
|
|
MX2022013391A
(es)
|
2020-04-24 |
2022-11-30 |
Astrazeneca Ab |
Pauta posologica para el tratamiento del cancer.
|
|
WO2021253380A1
(en)
*
|
2020-06-19 |
2021-12-23 |
InventisBio Co., Ltd. |
Oral formulations and uses thereof
|
|
IL300397A
(en)
|
2020-08-05 |
2023-04-01 |
C4 Therapeutics Inc |
Compounds for targeted knockdown of RET
|
|
MX2023001572A
(es)
*
|
2020-08-05 |
2023-05-08 |
Aizant Drug Res Solutions Private Limited |
Formas farmaceuticas sólidas de palbociclib.
|
|
EP4247977A2
(en)
|
2020-11-23 |
2023-09-27 |
Sanofi |
Panel of er regulated genes for use in monitoring endocrine therapy in breast cancer
|
|
EP4267578A4
(en)
|
2020-12-23 |
2024-11-20 |
Recurium IP Holdings, LLC |
ESTROGEN RECEPTOR MODULATORS
|
|
MX2023011241A
(es)
|
2021-03-23 |
2023-10-03 |
Nuvation Bio Inc |
Compuestos dirigidos a receptores de hormonas nucleares contra el cancer.
|
|
JP2024516024A
(ja)
|
2021-05-03 |
2024-04-11 |
ニューベイション・バイオ・インコーポレイテッド |
抗がん核内ホルモン受容体標的化化合物
|
|
MX2023014059A
(es)
|
2021-06-08 |
2024-03-12 |
C4 Therapeutics Inc |
Terapeuticos para la degradacion de una proteina quiinasa de serina/ treonina mutante.
|
|
WO2023283329A1
(en)
*
|
2021-07-08 |
2023-01-12 |
Olema Pharmaceuticals, Inc. |
Methods of treating estrogen receptor-associated diseases
|
|
AU2022307207A1
(en)
|
2021-07-09 |
2024-02-15 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Salt types of tricyclic tetrahydro isoquinoline derivative
|
|
WO2023221123A1
(en)
*
|
2022-05-20 |
2023-11-23 |
Olema Pharmaceuticals, Inc. |
Crystalline forms of an estrogen receptor antagonist
|
|
WO2024030968A1
(en)
|
2022-08-03 |
2024-02-08 |
Brystol-Myers Squibb Company |
Compounds for modulating ret protein
|
|
WO2024097980A1
(en)
|
2022-11-04 |
2024-05-10 |
Bristol-Myers Squibb Company |
Ret-ldd protein inhibitors
|
|
EP4611901A1
(en)
|
2022-11-04 |
2025-09-10 |
Bristol-Myers Squibb Company |
Ret-ldd protein degraders
|
|
KR20240170460A
(ko)
*
|
2023-05-25 |
2024-12-03 |
주식회사 삼양홀딩스 |
팔보시클립의 경구용 조성물
|
|
EP4735452A2
(en)
|
2023-06-30 |
2026-05-06 |
Merck Patent GmbH |
Heterobifunctional compounds for the degradation of kras protein
|
|
TW202543650A
(zh)
|
2024-03-08 |
2025-11-16 |
美商海爾達醫療運營公司 |
異雙官能化合物及其在治療疾病中之用途
|